SCHEMBL77969

SCHEMBL77969

C1CCC[C](C2CCCCCC2)CCC1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.36
NISCH Q9Y2I1 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
DAO P14920 1/20 0.30
CYP11B2 P19099 1/20 0.30
DPP7 Q9UHL4 1/20 0.30
TRIM24 O15164 1/20 0.30
TRIM33 Q9UPN9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7737845 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL61818 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL542776 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL13858690 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL9956415 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL25327994 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL7340365 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL11594630 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL625943 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4
SCHEMBL61394 1.00 KMT2A (0.36) KMT2ANISCHCA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117222637-A EGFR degrading agents and related methods of use 百济神州有限公司 2023-12-12 CN claimed
CN-113999158-B 3- (1-hydroxyalkylene) indolone and preparation method thereof 延边大学 2023-08-01 CN claimed
EP-2513086-A1 NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2012-10-24 EP claimed
EP-2513093-A1 NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2012-10-24 EP claimed
US-20110212960-A1 NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-01 US claimed
WO-2011073154-A1 NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-23 WO claimed
WO-2011073155-A1 NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-23 WO claimed
WO-2011018495-A1 NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 WO claimed
EP-1237850-B1 GLYOXYL ACID AMIDES BAYER CROPSCIENCE AG (DE) 2005-02-09 EP claimed
EP-1237850-A2 GLYOXYL ACID AMIDES Bayer Aktiengesellschaft (DE) 2002-09-11 EP claimed
US-6313173-B1 USED AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2001-11-06 US claimed
WO-2001039787-A2 GLYOXYL ACID AMIDES, METHOD FOR PRODUCING THEM AND THEIR USE FOR CONTROLLING HARMFUL ORGANISMS BAYER AKTIENGESELLSCHAFT (DE) 2001-06-07 WO claimed
EP-0989971-A1 GLYOXYLIC ACID AMIDES Bayer Aktiengesellschaft (DE) 2000-04-05 EP claimed
EP-0946504-A1 COMPOUNDS USEFUL FOR PERHALOGENOALKYLATION, REAGENT FOR IMPLEMENTING THESE COMPOUNDS AND SYNTHESIS METHOD FOR OBTAINING THESE COMPOUNDS RHODIA CHIMIE (FR) 1999-10-06 EP claimed
EP-0941215-A1 GLYOXYLIC ACID AMIDES AND THEIR USE AS PESTICIDES BAYER AG (DE) 1999-09-15 EP claimed
WO-1998058903-A1 GLYOXYLIC ACID AMIDES BAYER AKTIENGESELLSCHAFT (DE) 1998-12-30 WO claimed
WO-1998022434-A1 GLYOXYLIC ACID AMIDES BAYER AKTIENGESELLSCHAFT (DE) 1998-05-28 WO claimed
WO-1998022435-A1 COMPOUNDS USEFUL FOR PERHALOGENOALKYLATION, REAGENT FOR IMPLEMENTING THESE COMPOUNDS AND SYNTHESIS METHOD FOR OBTAINING THESE COMPOUNDS RHODIA CHIMIE (FR) 1998-05-28 WO claimed
US-11999754-B2 Ruthenium complexes and their use in olefin metathesis reactions APEIRON SYNTHESIS S.A. (PL) 2024-06-04 US disclosed
US-3962201-A PROCESS FOR POLYMERIZING ACRYLICS EMPLOYING (HYDROCARBON-PEROXY HYDROCARBON) PHOSPHONATES S. A. TEXACO BELGIUM N.V. (BE) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999754-B2 Ruthenium complexes and their use in olefin metathesis reactions ADH1A, CYP2E1, OPRM1 KMT2A 4018/4885NISCH 1086/4885CA1 1350/4885
US-20110212960-A1 NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER BDNF, PSEN1, CHRNA5 KMT2A 1624/4885NISCH 99/4885CA1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.